Navigation Links
Genoptix Reports Strong Financial Results for First Quarter 2008
Date:5/8/2008

,276 1,409

Total current assets 101,151 95,882

Property and equipment, net 3,096 1,950

Other long-term assets 78 -

Total assets $104,325 $97,832

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable and accrued expenses $5,691 $4,312

Accrued compensation 2,312 2,496

Deferred revenues 68 95

Total current liabilities 8,071 6,903

Deferred rent, net of current portion 332 324

Commitments and contingencies

Stockholders' equity:

Preferred stock - -

Common stock 16 16

Additional paid-in capital 132,853 132,532

Accumulated other comprehensive income 42 53

Accumulated deficit (36,989) (41,996)

Total stockholders' equity 95,922 90,605

Total liabilities and stockholders' equity $104,325 $97,832

GENOPTIX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

(in thousands, except per share data)

Three Months Ended

March 31,

2008 2007

Revenues $22,298 $10,651

Cost of revenues
'/>"/>

SOURCE Genoptix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Genoptix, Inc. Announces Pricing for Initial Public Offering
2. Genoptix, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 12, 2008
3. Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007
4. Genoptix Announces Filing of Registration Statement for Secondary Public Offering of Common Stock
5. Genoptix Announces Pricing of Secondary Public Offering
6. Genoptix Announces Participation at Cowen and Company 28th Annual Health Care Conference
7. Genoptix Announces Participation at Lehman Brothers 11th Annual Global Health Care Conference
8. Genoptix Announces 2008 Annual Stockholders Meeting and Date of Record
9. Genoptix Announces Participation at the Bank of America 2008 Healthcare Conference
10. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
11. Haemacure Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:TNF-Alpha Inhibitors Are Being Used More Often To Treat Newly Diagnosed Patients With Crohn's Disease 2TNF-Alpha Inhibitors Are Being Used More Often To Treat Newly Diagnosed Patients With Crohn's Disease 3Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 2Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 3Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 4Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 5Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 6Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 7Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 8Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 9Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 10Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 11Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 12Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 13New HHS HRSA Grant Will Fund Development of an Electronic Genetic and Family History Record for Doctors Offices 51651 1New HHS HRSA Grant Will Fund Development of an Electronic Genetic and Family History Record for Doctors Offices 51651 2New HHS HRSA Grant Will Fund Development of an Electronic Genetic and Family History Record for Doctors Offices 51651 3Pederson Immigration Law Group Attorneys Featured in 14th Annual J 1 H 1B Foreign Physician Immigration Conference and Job Fair Series 51648 1Pederson Immigration Law Group Attorneys Featured in 14th Annual J 1 H 1B Foreign Physician Immigration Conference and Job Fair Series 51648 2Pederson Immigration Law Group Attorneys Featured in 14th Annual J 1 H 1B Foreign Physician Immigration Conference and Job Fair Series 51648 3meridianEMR Completes Surescripts 28R 29 Certification 51645 1meridianEMR Completes Surescripts 28R 29 Certification 51645 2meridianEMR Completes Surescripts 28R 29 Certification 51645 3